425,000 Shares in Equillium, Inc. $EQ Bought by Cantor Fitzgerald L. P.

Cantor Fitzgerald L. P. purchased a new stake in Equillium, Inc. (NASDAQ:EQ) in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor purchased 425,000 shares of the company’s stock, valued at approximately $608,000. Cantor Fitzgerald L. P. owned approximately 0.70% of Equillium at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. ADAR1 Capital Management LLC purchased a new stake in shares of Equillium in the third quarter worth about $7,951,000. Woodline Partners LP purchased a new stake in shares of Equillium during the 3rd quarter valued at about $5,018,000. Vanguard Group Inc. raised its holdings in shares of Equillium by 59.4% during the 3rd quarter. Vanguard Group Inc. now owns 1,313,946 shares of the company’s stock valued at $1,879,000 after buying an additional 489,855 shares during the period. Aberdeen Group plc acquired a new position in Equillium during the 3rd quarter worth approximately $543,000. Finally, Two Sigma Investments LP acquired a new position in Equillium during the 3rd quarter worth approximately $190,000. Institutional investors and hedge funds own 27.05% of the company’s stock.

Insider Activity at Equillium

In other news, COO Christine Zedelmayer sold 185,937 shares of the stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $1.76, for a total transaction of $327,249.12. Following the completion of the transaction, the chief operating officer directly owned 191,444 shares in the company, valued at approximately $336,941.44. This represents a 49.27% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In the last three months, insiders sold 594,001 shares of company stock worth $1,148,895. Corporate insiders own 31.60% of the company’s stock.

Equillium Stock Down 0.9%

Shares of NASDAQ EQ opened at $2.13 on Thursday. Equillium, Inc. has a fifty-two week low of $0.27 and a fifty-two week high of $2.70. The business has a 50 day moving average price of $1.59 and a two-hundred day moving average price of $1.42. The firm has a market cap of $129.70 million, a PE ratio of -3.44 and a beta of 1.81.

Analysts Set New Price Targets

Several brokerages have issued reports on EQ. Zacks Research raised shares of Equillium to a “hold” rating in a research report on Thursday, February 26th. Stifel Nicolaus started coverage on shares of Equillium in a research report on Wednesday, February 25th. They set a “buy” rating and a $5.00 target price on the stock. Wall Street Zen raised shares of Equillium from a “sell” rating to a “hold” rating in a report on Saturday, March 14th. Roth Mkm began coverage on shares of Equillium in a research note on Friday, March 13th. They set a “buy” rating and a $12.00 price target on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Equillium in a report on Monday, December 29th. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $6.00.

Equillium Profile

Equillium, Inc (NASDAQ: EQ) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat severe autoimmune diseases and prevent organ transplant rejection. The company’s lead therapeutic candidate, EQ001 (itolizumab), is a humanized monoclonal antibody that modulates T-cell activation by targeting the CD6 receptor. Equillium’s pipeline also includes additional biologic candidates aimed at addressing indications such as acute graft-versus-host disease (GVHD) and lupus nephritis.

Founded in 2015 and headquartered in La Jolla, California, Equillium in-licensed itolizumab from Biocon Limited, leveraging the antibody’s established safety profile in earlier clinical studies.